What is a stock summary page? Click here for an overview.
Business Description
Poseida Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US73730P1084
Share Class Description:
PSTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
PSTX.USA2RZ.Germany Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2020-07-10Description
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.79 | |||||
| Equity-to-Asset | 0.3 | |||||
| Debt-to-Equity | 0.95 | |||||
| Debt-to-EBITDA | -1.79 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 0.33 | |||||
| Beneish M-Score | -1.88 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 29.4 | |||||
| 3-Year EPS without NRI Growth Rate | 27.6 | |||||
| 3-Year FCF Growth Rate | 33.7 | |||||
| 3-Year Book Growth Rate | -36.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -35.97 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.11 | |||||
| 9-Day RSI | 66.38 | |||||
| 14-Day RSI | 75.33 | |||||
| 3-1 Month Momentum % | 264.2 | |||||
| 6-1 Month Momentum % | 215.15 | |||||
| 12-1 Month Momentum % | 189.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.2 | |||||
| Quick Ratio | 3.2 | |||||
| Cash Ratio | 2.95 | |||||
| Days Sales Outstanding | 27.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.6 | |||||
| Shareholder Yield % | 0.37 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -41.43 | |||||
| Net Margin % | -40.28 | |||||
| FCF Margin % | -11.35 | |||||
| ROE % | -66.04 | |||||
| ROA % | -21.23 | |||||
| ROIC % | -61.75 | |||||
| 3-Year ROIIC % | -13 | |||||
| ROC (Joel Greenblatt) % | -131.01 | |||||
| ROCE % | -25.38 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.12 | |||||
| PB Ratio | 10.61 | |||||
| Price-to-Tangible-Book | 11.31 | |||||
| EV-to-EBIT | -15.06 | |||||
| EV-to-EBITDA | -16.85 | |||||
| EV-to-Revenue | 5.16 | |||||
| EV-to-Forward-Revenue | 20.52 | |||||
| EV-to-FCF | -45.42 | |||||
| Price-to-GF-Value | 1.73 | |||||
| Price-to-Net-Current-Asset-Value | 20.65 | |||||
| Price-to-Net-Cash | 38 | |||||
| Earnings Yield (Greenblatt) % | -6.64 | |||||
| FCF Yield % | -1.85 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PSTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Poseida Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 150.858 | ||
| EPS (TTM) ($) | -0.62 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 0.53 | ||
| 3-Year Sortino Ratio | 1.93 | ||
| Volatility % | 299.57 | ||
| 14-Day RSI | 75.33 | ||
| 14-Day ATR ($) | 0.184979 | ||
| 20-Day SMA ($) | 9.487 | ||
| 12-1 Month Momentum % | 189.78 | ||
| 52-Week Range ($) | 1.87 - 9.67 | ||
| Shares Outstanding (Mil) | 97.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Poseida Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Poseida Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Poseida Therapeutics Inc Frequently Asked Questions
What is Poseida Therapeutics Inc(PSTX)'s stock price today?
The current price of PSTX is $9.50. The 52 week high of PSTX is $9.67 and 52 week low is $1.87.
When is next earnings date of Poseida Therapeutics Inc(PSTX)?
The next earnings date of Poseida Therapeutics Inc(PSTX) is 2025-05-14 Est..
Does Poseida Therapeutics Inc(PSTX) pay dividends? If so, how much?
Poseida Therapeutics Inc(PSTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers